Skip to main content
SpringerLink
Log in

The oral antiarrhythmic drugs

  • Chapter
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

Part of the book series: Progress in Drug Research ((PDR,volume 35))

  • 101 Accesses

Abstract

Over the past few years, many new antiarrhythmic drugs have been developed, expanding the choices available for treating arrhythmia. However, at the same time, there has been confusion about how to choose an appropriate drug for the individual patient. Unfortunately, there are no reliable guidelines available for drug selection and there are no drugs which are specific for certain arrhythmias or groups of patients. Drug therapy is empiric and the beneficial or harmful effects of one drug do not provide any information about the response to any other agent. It is therefore necessary to know about the actions and side effects of each drug.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. C. M. Chen, L. S. Gettes, B. G. Katzung: Effect of lidocaine and quinidine on steady state characteristics and recovery kinetics of dv/dt,,,a, in guinea pig ventricular myocardium. Circ Res 37: 20, 1975.

    Google Scholar 

  2. M. R. Rosen, A. L. Wit: Electropharmacology of antiarrhythmic drugs. Am Heart J 106: 829, 1983.

    Google Scholar 

  3. B. F. Hoffman, M. R. Rosen: Cellular mechanism for cardiac arrhythmias. Circ Res 49: 1, 1981.

    Google Scholar 

  4. A. Norma, H. Irisawa, S. Kokubun, H. Kotake, M. Nishimara, Y. Watanabe: Slow current systems in the AV node of the rabbit heart. Nature 285: 228, 1980.

    Google Scholar 

  5. A. L. Wit, M. R. Rosen: Pathophysiologic mechanisms of cardiac arrhythmias. Am Heart J 106: 798, 1983.

    Google Scholar 

  6. R. F. Gilmour, J. J. Heger, E. N. Prystowsky, D. P. Zipes: Cellular electrophysiological abnormalities of diseased human ventricular myocardium. Am J Cardiol 51: 137, 1983.

    Google Scholar 

  7. P. F. Cranefield: Action potentials, afterpotentials and arrhythmias. Circ Res 41: 415, 1977.

    Google Scholar 

  8. A. L. Wit, P. F. Cranefield: Triggered activity in cardiac muscle fibers of the simian mitral valve. Circ Res 38: 85, 1976.

    Google Scholar 

  9. A. L. Wit, P. F. Cranefield: Reentrant excitation as a cause of cardiac arrhythmias. Am J Physiol 235: H1, 1978.

    Google Scholar 

  10. E. M. Vaughan Williams: Classification of antiarrhythmic drugs. In: E. Sandoe, E. Flensted-Jensen, E. Olsen, eds. Symposium on cardiac arrhythmias. Sodertalje, Sweden: AB Astra, pp. 449–472, 1970.

    Google Scholar 

  11. B. F. Hoffman, M. R. Rosen, A. L. Wit: Electrophysiology and pharmacology of cardiac arrhythmias: 7. cardiac effects of quinidine and procainamide. Am Heart J 90: 117, 1975.

    Google Scholar 

  12. D. C. Harrison: Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol 56: 185, 1985.

    Google Scholar 

  13. L. M. Hondeghem, B. C. Katzang: Time and voltage dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochem Biophys Acta 472: 383, 1977.

    Google Scholar 

  14. A. L. Wit, B. F. Hoffman, M. R. Rosen: Electrophysiology and pharmacology of cardiac arrhythmias: 9. Cardiac electrophysiologic effects of beta-adrenergic receptor stimulation and blockade: Part C. Am Heart J 90: 797, 1975.

    Google Scholar 

  15. G. S. Hirsowitz, P. Podrid, S. Lampert, J. Stein, B. Lown: The use of beta blocking agents as adjunct therapy in the treatment of malignant ventricular arrhythmia. J Am Coll Cardiol 3: 619, 1984.

    Google Scholar 

  16. P. J. Podrid, B. Lown: Use of beta-adrenergic blocking agents for cardiac arrhythmias. In: J. P. Kostis, E. A. DeFelice, eds. Beta blockers in the treatment of cardiovascular disease. New York: Raven Press, pp. 121–154, 1984.

    Google Scholar 

  17. B. N. C. Prichard, C. W. I. Owens: Clinical pharmacology of beta-adrenoceptor blocking drugs. In: J. P. Kostis, E. A. DeFelice, eds. Beta blockers in the treatment of cardiovascular disease. New York: Raven Press, pp. 1–56, 1984.

    Google Scholar 

  18. R. P. Swenson: Inactivation of potassium current in quid axon by a variety of quaternary ammonium ions. J Gen Physiol 77: 255, 1981.

    Google Scholar 

  19. M. B. Bacaner: Bretylium totylate for suppression of induced ventricular fibrillation. Am J Cardiol 17: 528, 1966.

    Google Scholar 

  20. A. L. Wit, P. Cranefield: Effects of verapamil in the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia. Circ Res 35: 413, 1974.

    Google Scholar 

  21. M. R. Rosen, A. L. Wit, B. F. Hoffmann: Electrophysiology and pharmacology of cardiac arrhythmias: 6. Cardiac effects of verapamil. Am Heart J 89: 665, 1975.

    Google Scholar 

  22. B. N. Singh, H. S. Hecht, K. Nademanee: Electrophysiologic and hemodynamic actions of slow channel blocking compounds. Prog Cardiovasc Dis 25: 103, 1982.

    Google Scholar 

  23. R. L. Sung, B. Elser, R. G. McAllister: Intravenous verapamil for termination of reentrant supraventricular tachycardias. Ann Intern Med 93: 682, 1980.

    Google Scholar 

  24. V. Velebit, P. J. Podrid, B. Lown, B. Cohen, T. B. Graboys: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circ 65: 886, 1982.

    Google Scholar 

  25. D. P. Zipes: Proarrhythmic effects of antiarrhythmic drugs. Am J Cardiol 59: 26E, 1987.

    Google Scholar 

  26. R. F. Poser, P. J. Podrid, F. Lombardi, B. Lown: Aggravation of arrhythmias induced by antiarrhythmic drugs during electrophysiologic testing. Am Heart J 110: 4, 1985.

    Google Scholar 

  27. P. J. Podrid, S. Lampert, T. B. Graboys, C. M. Blatt, B. Lown: Aggravation of arrhythmia by antiarrhythmic drugs — Incidence and predictors. Am J Cardial 59: 31E, 1987.

    Google Scholar 

  28. W. Slater, S. Lambert, P. J. Podrid, B. Lown: Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 61: 349, 1988.

    Google Scholar 

  29. J. Morganroth: Risk factors for the development of proarrhythmic events. Am J Cardiol 59: 32E, 1987.

    Google Scholar 

  30. J. Morganroth, L. N. Norowitz: Flecainide — its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53: 893, 1984.

    Google Scholar 

  31. P. J. Podrid, F. J. Vendetti, P. A. Levine, M. D. Klein: The role of exercise testing in evaluation of arrhythmias. Am J Cardiol 62: 24H, 1988.

    Google Scholar 

  32. J. Ravid, P. J. Podrid, S. Lampert, B. Lown: Congestive heart failure induced by six of the new antiarrhythmic drugs. J Am Coll Cardiol 14: 1326, 1989.

    Google Scholar 

  33. L. D. Nelson, P. G. Schmid, D. Holmsten, A. L. Mark, D. D. Heistad, F. M. Abboud. Effects of quinidine on venous responses to adrenergic and nonadrenergic constrictor stimuli: indirect evidence of two sites of action in vascular smooth muscle. Proc Soc Exp Biol Med 146: 409, 1974.

    Google Scholar 

  34. A. J. Leach, J. E. Brown, P. W. Armstrong: Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. Am J Med 68: 839, 1980.

    Google Scholar 

  35. Bigger (Ed): A symposium: Flecainide Acetate. Am J Cardiol 53: (suppl B), 1984.

    Google Scholar 

  36. A. B. Hodess, W. P. Follansbee, J. F. Spear, E. N. Moore: Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart. J Cardiovasc Pharmacol 1: 427, 1979.

    Google Scholar 

  37. B. N. Singh, K. Nademanee, M. A. Josephson, N. Ikeda, N. Venkatish, L. Kannan: The electrophysiology and pharmacology of verapamil, flecainide and amiodarone: Correlations with clinical effects and antiarrhythmic actions. In Garfein OB. Clinical Pharmacology of Cardiac Antiarrhythmic Agents. Classical and recent concepts reevaluated. New York: NY Academy of Sciences, Vol 432, pp. 210–235, 1984.

    Google Scholar 

  38. P. I. Hoff, A. Tronstadt, B. Oil, O. J. Ohm: Electrophysiology and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardias. Am J Cardiol 62: 585, 1988.

    Google Scholar 

  39. G. J. Conrad, R. E. Ober: Metabolism of flecainide. Am J Cardiol 53: 41B, 1984.

    Google Scholar 

  40. M. A. Josephson, N. Ikeda, B. N. Singh: Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol 53: 95B, 1984.

    Google Scholar 

  41. M. A. Josephson, S. Kaul, J. Hopkins, D. Kvam, B. Singh: Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J 109: 41, 1985.

    Google Scholar 

  42. P. H. J. M. Dunselman, J. H. Ingma, L. M. van Wijk, A. Disk, J. Wesseling, K. I. Lie: Hemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure. Drugs (suppl 4 ): 58, 1985.

    Google Scholar 

  43. J. L. Anderson, J. R. Stewart, B. A. Perry, D. D. van Hamersveld, T. A. Johnson, G. J. Conard: Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305: 473, 1981.

    Google Scholar 

  44. M. Hodges, J. M. Haugland, G. Granrud, G. J. Conard, R. W. Asinger, F. L. Mikell: Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. Circulation 65: 879, 1982.

    Google Scholar 

  45. J. Kjekshus, J. Bathen, O. M. Orning, L. Storstein: A double blind crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature beats. Am J Cardiol 53: 72B, 1984.

    Google Scholar 

  46. The Flecainide-Quinidine Research Group. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circ 67: 1117, 1983.

    Google Scholar 

  47. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406, 1989.

    Google Scholar 

  48. P. R. Reid, L. S. C. Griffith, E. V. Platia, E. S. Ord: Evaluation of flecainide acetate in management of patients at high risk of sudden cardiac death. Am J Cardiol 53: 108B, 1988.

    Google Scholar 

  49. Flecainide Ventricular Tachycardia Study Group. Treatment of resistant ventricular tachycardia with flecainide acetate. Am J Cardiol 57: 1299, 1986.

    Google Scholar 

  50. S. S. Kim, R. Lal, R. Ruffy: Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol 58: 80, 1986.

    Google Scholar 

  51. J. L. Anderson, E. L. L. Pritchett (Ed.): International Symposium on Su- praventricular Arrhythmias: Focus on flecainide. 62: Suppl D, 1988.

    Google Scholar 

  52. G. D. Gentzkow, J. Y. Sullivan: Extracardiac adverse effects of flecainide. Am J Cardiol 53: 101B, 1984.

    Google Scholar 

  53. J. Morganroth, D. C. Harrison (Ed.): A Symposium — Encainide. Am J Cardiol 58: Suppl C, 1986.

    Google Scholar 

  54. G. V. Naccarelli, H. J. J. Wellens (Ed.): A Symposium: The use of encainide in supraventricular tachycardias. Am J Cardiol 62: Suppl C, 1988.

    Google Scholar 

  55. M. Sami, J. W. Mason, G. Oh, D. C. Harrison: Canine electrophysiology of encainide, a new antiarrhythmic drug. Am J Cardiol 43: 1149, 1979.

    Google Scholar 

  56. R. A. Winkle, F. A. Peters, R. E. Kates, D. C. Harrison: Possible contribution of encainide metabolites to the antiarrhythmic efficacy of encainide. Am J Cardiol 51: 1182, 1983.

    Google Scholar 

  57. J. T. Barbey, K. A. Thompason, D. S. Echt, R. L. Woosley, D. M. Roden: Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites, 0-desmethyl encainide and 3 methoxy0-desmethyl encainide in man. Circ 77: 380, 1988.

    Google Scholar 

  58. R. A. Winkle, F. Peters, R. E. Kates, C. Tucker, D. C. Harrison: Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circ 64: 290, 1981.

    Google Scholar 

  59. T. Wang, D. M. Roden, H. T. Wolfendin, R. L. Woosley, A. J. J. Wood, G. R. Wilkenson: Influence of genetic polymorphism on the metabolites and disposition of encainide in man. J Pharmacol Exp Ther 228: 605, 1984.

    Google Scholar 

  60. R. H. Bergstrand, T. Wang, D. M. Roden, G. R. Avant, W. W. Sutton, L. A. Siddoway, H. Wolfenden, R. L. Woosley, G. R. Wilkenson, A. J. J. Wood: Encainide disposition in patients with chronic cirrhosis. Clin Pharmacol Ther 40: 148, 1986.

    Google Scholar 

  61. A. H. Bergstrand, T. Wang, D. M. Roden, W. S. Stone, H. T. Wolfinden, R. L. Woosley, G. R. Wilkinson, A. J. J. Wood: Encainide disposition in patients with renal failure. Clin Pharmacol Ther 40: 64, 1986.

    Google Scholar 

  62. B. D. Quart, D. G. Gallo, M. H. Sami, A. J. J. Wood: Drug interaction studies and encainide use in renal and hepatic impairment. Am J Cardiol 58: 104C, 1986.

    Google Scholar 

  63. M. H. Sami, V. A. Derbekyan, R. Lisbona: Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function. Am J Cardiol 52: 507, 1983.

    Google Scholar 

  64. S. S. Gottlieb, M. L. Kukin, M. Yushak, N. Medina, M. Packer: Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Ann Int Med 110: 505, 1989.

    Google Scholar 

  65. J. Morganroth, P. E. Pool, R. Miller, P. H. Hsu, I. K. Lee, D. M. Clark: Dose responsive range of encainide for benign and potentially lethal ventricular arrhythmias. Am J Cardiol 57: 769, 1986.

    Google Scholar 

  66. D. M. Roden, B. R. Stots, S. B. Higgins, R. F. Mayol, R. E. Gammans, J. A. Oates, R. L. Woosley: Total suppression of ventricular arrhythmias by encainide. N Engl J Med 302: 877, 1980.

    Google Scholar 

  67. R. DiBianco, R. D. Fletcher, A. I. Cohen, J. S. Gottdiener, S. N. Singh, J. H. Katz: Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests and radionuclide angiographic studies. Circ 65: 1134, 1982.

    Google Scholar 

  68. J. Morganroth, J. C. Somberg, P. E. Pool, P. H. Hsu, I. K. Lee, J. Durkee: Comparative study of encainide and quinidine in the treatment of ventricular arrhythmia. J Am Coll Cardiol 7: 9, 1986.

    Google Scholar 

  69. T. Tordjman, P. J. Podrid, E. Raeder, B. Lown: Safety and efficacy of encainide for malignant ventricular arrhythmias. Am J Cardiol 58: 87C, 1986.

    Google Scholar 

  70. L. N. Horowitz: Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms. Am J Cardiol 58: 83C, 1986.

    Google Scholar 

  71. J. W. Mason, F. Peters: Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circ 63: 670, 1981.

    Google Scholar 

  72. W M. Miles, D. P. Zipes, R. L. Rinkenberger, M. L. Markel, E. N. Prystowsky, A. H. Dougherty, J. J. Heger, G. V. Naccarelli: Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff Parkinson White Syndrome. Am J Cardiol 62: 20C, 1988.

    Google Scholar 

  73. G. V. Naccarelli, W. M. Jackman, M. Akhtar, R. L. Rinkenberger, K. J. Friday, A. H. Dougherty, P. Tchou, J. A. Yiung-Lei-Wak: Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia. Am J Cardiol 62: 312, 1988.

    Google Scholar 

  74. K. P. Kunzl, K. H. Kuck, M. Schluter: The effect of encainide and flecainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol 7: 1121, 1986.

    Google Scholar 

  75. R. L. Rinkenberger, G. V. Naccarelli, W. M. Miles, M. L. Markel, A. H. Dougherty, E. N. Prystowsky, J. J. Heger, D. P. Zipes: Encainide for atrial fibrillation associated with Wolff Parkinson White Syndrome. Am J Cardiol 62: 264, 1988.

    Google Scholar 

  76. L. F. Soyka: Safety of encainide for treatment of ventricular arrhythmias. Am J Cardiol 58: 96C, 1986.

    Google Scholar 

  77. R. A. Winkle, J. W. Mason, J. C. Griffin, D. Ross: Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 102: 857, 1981.

    Google Scholar 

  78. P. J. Podrid (Ed.): Symposium on Propafenone. J Electrophy 1:501, 1987.

    Google Scholar 

  79. Zipes (Ed.): Symposium on Propafenone. Am J Cardiol 54: Suppl D, 1984.

    Google Scholar 

  80. M. Kohlhardt: Block of sodium currents by antiarrhythmic agents. Analysis of the electrophysiologic effects of propafenone. Am J Cardiol 54:, 1984.

    Google Scholar 

  81. H. Muller-Piltzer, G. Greger, G. Neugebauer, M. Holtman: Beta blocking and electrophysiologic effects of propafenone in volunteers. Eur Heart J 6: 123, 1985.

    Google Scholar 

  82. A. A. McLeod, G. L. Stiles, D. G. Shand: Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: Clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharma-col Exp Ther 228: 461, 1984.

    Google Scholar 

  83. F. Ledda, L. Mantelli, S. Manzini, S. Amerini, A. Mugelli: Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 3: 1162, 1981.

    Google Scholar 

  84. I. D. Dukes, E. M. Vaughan Williams: The multiple modes of action of propafenone. Eur Heart J 5: 115, 1984.

    Google Scholar 

  85. S. J. Connolly, R. E. Kates, C. S. Lebsack, D. S. Echt, J. W. Mason, R. A. Winkle: Clinical effifacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 52: 1208, 1983.

    Google Scholar 

  86. L. Seipel, Breithardt. Propafenone — a new antiarrhythmic drug. Eur Heart J 1: 309, 1980.

    Google Scholar 

  87. N. A. Smith, R. E. Kates, D. C. Harrison: The clinical pharmacology of propafenone. J Electrophysiol 1: 517, 1987.

    Google Scholar 

  88. S. J. Connolly, R. E. Kates, C. S. Lebsack: Clinical pharmacology of propafenone. Circ 68: 589, 1983.

    Google Scholar 

  89. C. A. Siddoway, D. M. Roden, R. L. Woosley: Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration — response relations. Am J Cardiol 54: 9D, 1984.

    Google Scholar 

  90. J. L. Stohler, P. R. Kowey, R. A. Marinchak, T. D. Friehling: Drug interactions with propafenone. J Electrophysiol 1: 568, 1987.

    Google Scholar 

  91. D. M. Salerno, G. Granrud, P. Sharkey, R. Asinger, M. A. Hodges: A controlled trial of propafenone for the treatment of frequent and repetitive ventricular premature contractions. Am J Cardiol 53: 77, 1984.

    Google Scholar 

  92. R. L. Klein, F. I. Marcus: Efficacy of propafenone when used in combination antiarrhythmjc therapy. J Electrophysiol 1: 575, 1987.

    Google Scholar 

  93. B. J. Baker, H. Dinh, D. Kroskey, N. D. B. de Soza, M. C. Murphy, J. A. Franciosa: Effect of propafenone on left ventricular ejection fraction. Am J Cardiol 54: 20D, 1984.

    Google Scholar 

  94. M. A. Brodsky, B. J. Allen, D. Abate, W. L. Henry: Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Am Heart J 110: 794, 1985.

    Google Scholar 

  95. N. deSoyza, C. Terry, M. L. Murphy: Effects of propafenone in patients with stable ventricular arrhythmias. Am Heart J 108: 285, 1984.

    Google Scholar 

  96. M. Hodges, D. Salerno, G. Granrud: Double blind placebo-controlled evaluations of propafenone in suppressing ventricular ectopic activity. Am J Cardiol 54: 45D, 1984.

    Google Scholar 

  97. F. Naccarelli, D. Bracchetti, M. Palmieri: A Comparison of propafenone and disopyramide for threatment of chronic ventricular arrhythmias: palacebo controlled, double-blind, randomized crossover study. Am Heart J 109: 833, 1985.

    Google Scholar 

  98. H. A. Dinh, M. L. Murphy, B. J. Baker: Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias. Am J Cardiol 55: 1520, 1985.

    Google Scholar 

  99. P. J. Podrid, B. Lown: Propafenone: A new agent for ventricular arrhythmia. J Am Coll Cardiol 4: 117, 1984.

    Google Scholar 

  100. L. Cueni, P. J. Podrid: Propafenone therapy in patients with serious ventricular arrhythmia. Noninvasive evaluation of efficacy. J Electrophysiol 1: 548–560, 1987.

    Google Scholar 

  101. D. A. Chilson, J. J. Heger, D. P. Zipes, E. N. Prystowsky: Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J Am Coll Cardiol 5: 1407, 1985.

    Google Scholar 

  102. L. Fananpazir, E. N. Prystowsky: Propafenone — clinical electrophysiology and efficacy in patients with documented or potentially life threatening arrhythmias. — J Electrophysiol 1: 543–547, 1987.

    Google Scholar 

  103. S. C. Hammil: Use of propafenone in patients with supraventricular tachycardia. J Electrophysiol 1: 561, 1987.

    Google Scholar 

  104. P. Coumel, S. F. Leclercq, P. Assayag: European experience with the antiarrhythmic effifacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 54: 60D, 1984.

    Google Scholar 

  105. E. N. Shen, E. Keung, E. Huycke: Intravenous propafenone for termination of reentrant supraventricular tachycardia: A placebo controlled randomized, double-blind, crossover study. Ann Int Med 105: 655, 1986.

    Google Scholar 

  106. G. Breithardt, M. Borggrefe, E. Wiebringhaus, L. Seipel: Effect of propafenone in the Wolff-Parkinson-White Syndrome: Electrophysiologic findings and long-term follow-up. Am J Cardiol 54: 29D, 1984.

    Google Scholar 

  107. S. Ravid, P. J. Podrid, B. Novrit: Safety of long-term propafenone therapy for cardiac arrhythmia: experience with 774 patients. J Electrophysiol 1: 580, 1987.

    Google Scholar 

  108. P. D. Dennis, E. M. Vaughan-Williams: Effects of rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent in normoxia and hypoxia. Br J Pharmacol 85: 11, 1985.

    Google Scholar 

  109. P. D. Dennis, E. M. Vaughan-Williams: The effects of indecainide, a new antiarrhythmic drug on nodal tissues in the isolated rabbit heart. J Cardiovasc Pharmacol 8: 1, 1986.

    Google Scholar 

  110. L. N. Horowitz, S. R. Spielman, L. R. Webb, J. Morganroth, A. M. Greenspan: The clinical electrophysiology of intravenous indecainide. Am Heart J 110: 784, 1985.

    Google Scholar 

  111. P. J. Podrid, S. Hohnloser, B. Lown: Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmias. Am J Cardiol 61: 764, 1988.

    Google Scholar 

  112. J. Krejci, G. Granrud, D. Salerno, D. Gresbach, M. Hodges: Indecainide, a dose-ranging efficacy trial for treatment of ventricular ectopic depolarization (abstr.). Cire 68:1I1–311, 1986.

    Google Scholar 

  113. L. A. Siddoway, R. H. Bergstrand, R. K. Drumm, D. M. Roden, R. L. Woosley: Antiarrhythmic efficacy, safety and pharmacokinetics of indecainide (abstr.). Circ 68: III, 1986.

    Google Scholar 

  114. J. Morganroth, for Indecainide-Disopyramide Research Group: Comparative efficacy and safety of indecainid versus disopyramide on ventricular arrhythmias (abstr.). Circ 74: 1I - 104, 1986.

    Google Scholar 

  115. I. Yamaguchi, B. N. Singh, W. J. Mandel: Electrophysiologic actions of mexiletine on isolated rabbit atra and canine ventricular muscle and Purkinje fibers. Cardiovasc Res 13: 288, 1979.

    Google Scholar 

  116. P. J. Podrid, J. Ruskin (Ed.): The role of oral mexiletine in the management of ventricular arrhythmias. Am Heart J 107: 1053, 1984.

    Google Scholar 

  117. F. M. Weld, J. T. Bigger, D. Swistel: Elextrophysiological effects of mexiletine (KO 1173) on ovine cardiac Purkinje fibers. J Pharmacol Exp Ther 210: 222, 1979.

    Google Scholar 

  118. S. Hereng, A. Bodewci, A. Wollenberger: Sodium current in freshly isolated and in cultured single rate myocardial cells. Frequency and voltage dependent block by mexiletine. J Mol Cell Cardiol 15: 431, 1983.

    Google Scholar 

  119. J. P. Allen, J. G. Kelly, R. G. G. James, R. G. Shanks, S. A. Zaidi: Comparison of the effects of lignocaine and mexiletine on experimental ventricular arrhythmias. Postgrad Med J 53: 35, 1977.

    Google Scholar 

  120. M. McComish, D. Kitsin, C. Robinson, D. E. Jewitt: Clinical electrophysiologic effects of mexiletine. Postgrad Med J 53 (suppl 1): 85, 1977.

    Google Scholar 

  121. J. C. Roos, D. U. A. Paalman, A. J. Dunning: Electrophysiologic effects of mexiletine in man. Postgrad Med J 53 (suppl 1): 92, 1977.

    Google Scholar 

  122. N. P. S. Campbell, J. G. Kelly, A. A. J. Adgey, R. G. Shanks: The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6: 103, 1978.

    Google Scholar 

  123. A. Pottage: Oral dosage schedules for mexiletine. Postgrad Med J 53 (suppl 1): 155, 1977.

    Google Scholar 

  124. V. Haselbarth, J. E. Doevendans, M. Wolf: Kinetics and bioavailability of mexiletine in healthy subjetcs. Clin Pharmacol Ther 29: 729, 1981.

    Google Scholar 

  125. A. H. Beckett, E. C. Chidomere: The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J 53 (suppl 1): 60, 1977.

    Google Scholar 

  126. P. Herzog, W. Holtermuller, T. Kasper, T. Meinertz, D. Trenk, E. Jahnchen: Absorption of mexiletine after treatment with gastric antacids. Br J Clin Pharmacol 14: 746, 1982.

    Google Scholar 

  127. L. M. V. Weng, P. J. Meffin, J. J. Grygiel, J. Smith, D. J. Birkett: Effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol 9: 505, 1980.

    Google Scholar 

  128. M. A. Kiddie, C. M. Kaye, P. Turner: The influence of urinary pH in the elimination of mexiletine. Br J Clin Pharmacol 1: 229, 1974.

    Google Scholar 

  129. E. B. Leahy, E. G. U. Giardina, J. T. Bigger: Effect of ventricular failure in steady state kinetics of mexiletine. Clin Res (abstr.) 26: 239, 1980.

    Google Scholar 

  130. P. J. Pentikainen, M. O. Halenin, M. J. Helin: Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur J Clin Pharmacol 25: 773, 1983.

    Google Scholar 

  131. P. J. Podrid, B. Lown: Mexiletine for ventricular arrhythmias. Am J Cardiol 47: 895, 1981.

    Google Scholar 

  132. E. J. Begg, P. M. Chinwah, C. Webb, R. O. Day, D. N. Wade: Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol 14: 219, 1982.

    Google Scholar 

  133. P. J. Pentikainen, I. H. Koivula, H. A. Hiltunen: Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 23: 261, 1982.

    Google Scholar 

  134. E. B. Leahey, J. A. Reiffel, E. G. V. Giardina, et al.: The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin: A prospective study. Ann Intern Med 92: 605, 1980.

    Google Scholar 

  135. H. J. Duff, D. Roden, R. K. Primm, J. A. Oates, R. L. Woosley: Mexiletine in the treatment of resistant ventricular arrhythmias: Enhancement of efficacy and dose reduction of dose related side effects by combination with quinidine. Circ 67: 1124, 1983.

    Google Scholar 

  136. E. B. Leahey, R. H. Heissenbuttel, E. G. V. Giardina, T. J. Bigger: Combined mexiletine and propranolol treatment of refractory ventricular tachycardia. Br Med J 281: 357, 1980.

    Google Scholar 

  137. J. Carlier: Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics. Acta Cardiol 25 (suppl): 81, 1980.

    Google Scholar 

  138. K. I. Saunamaki: Hemodynamic effects of a new anti-arrhythmic agent, mexiletine (Ko 1173) in ischemic heart disease. Cardiovasc Res 9: 788, 1975.

    Google Scholar 

  139. J. Stein, P. J. Podrid, B. Lown: Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 54: 575, 1984.

    Google Scholar 

  140. A. Waleffe, H. E. Kulbertus: The efficacy of intravenous mexiletine on ventricular ectopic activity. Acta Cardiol 32: 269, 1977.

    Google Scholar 

  141. R. G. Talbot, J. Nimmo, D. G. Jalian, R. A. Clark, J. M. M. Neilson, L. F. Prescott: Treatment of ventricular arrhythmias with mexiletine (Ko 1173). Lancet 2: 399, 1973.

    Google Scholar 

  142. R. G. Talbot, D. G. Julian, L. F. Prescot: Long-term treatment of ventricular arrhythmia with oral mexiletine. Am Heart J 91: 58, 1976.

    Google Scholar 

  143. N. P. S. Campbell, J. A. Kelly, A. A. Adgey, et al.: The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6: 103, 1978.

    Google Scholar 

  144. M. H. Schoenfeld, I. Whitford, B. McGovern, H. Garan, J. N Ruskin: Oral mexiletine in the treatment of refractory ventricular arrhythmias: The role of electrophysiology techniques. Am Heart J 107: 1071, 1984.

    Google Scholar 

  145. L. E. Waspe, H. L. Waxman, A. E. Buxton, M. E. Josephson: Mexiletine for control of drug-resistant ventricular tachycardia: Clinical and electrophysiologic results in 44 patients. Am J Cardiol 51: 1175, 1983.

    Google Scholar 

  146. J. Stein, P. J. Podrid, S. Lampert, G. Hirsowitz, B. Lown: Long-term mexiletine for ventricular arrhythmia. Am Heart J 107: 1091, 1984.

    Google Scholar 

  147. H. G. Smyllie, J. W. H. Doar, C. D. Head, et al.: A trial of intravenous and oral mexiletine in acute myocardial infarction. Eur J Clin Pharmacol 26: 537, 1984.

    Google Scholar 

  148. IMPACT Research Group: International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 4: 1148, 1984.

    Google Scholar 

  149. J. B. Singh, A. M. Rasul, A. Skah, et al.: Efficacy of mexiletine in chronic ventricular arrhythmia compared with quinidine: A single-blind, randomized trial. Am J Cardiol 53: 84, 1984.

    Google Scholar 

  150. G. Breithard, L. Seipel, J. Lersmacher: Comparative study of the antiarrhythmic efficacy of mexiletine and disopyramide in patients with chronic ventricular arrhythmias. J Cardiovasc Pharmacol 4: 276, 1982.

    Google Scholar 

  151. E. N. Moore, J. F. Spear, L. N. Horowitz, H. S. Feldman, R. A. Moller: Electrophysiologic properties of a new antiarrhythmic drug — tocainide. Am J Cardiol 49: 703, 1978.

    Google Scholar 

  152. J. L. Anderson, J. W. Mason, R. A. Winkle, P. J. Meffin, K. F. Fowles, F. Peters, D. C. Harrison: Clinical electrophysiologic effects of tocainide. Circ 57: 685, 1978.

    Google Scholar 

  153. D. G. McDevitt, R. S. Nies, G. R. Wilkinson, R. F. Smith, R. F. Woosley, J. A. Oates: Antiarrhythmic effects of lidocaine congener, tocainide, 2 amino-2’, 6’ propionoxylidide, in man. Clin Pharmacol Ther 19: 396, 1976.

    Google Scholar 

  154. R. A. Winkle, P. J. Meffin, J. W. Fitzgerald, D. C. Harrison: Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. Circ 54: 884, 1976.

    Google Scholar 

  155. C. Graffner, T. B. Conradson, S. Hofvendahl, L. Ryden: Pharmacokinetics of tocainide following intravenous and oral administration in healthy subjetcs and in patients with acute myocardial infarction. Clin Pharmacol Ther 27: 64, 1980.

    Google Scholar 

  156. D. J. Coltart, T. B. Berndt, R. Ternoff, D. C. Harrison: Antiarrhythmic circulatory effects of Astra W3609J: A new lidocaine like agent. Am J Cardiol 34: 35, 1974.

    Google Scholar 

  157. K. Swedberg, J. Pehrson, L. Ryden: Electrocardiographic and hemodynamic effects of tocainide in man. Eur J Pharmacol 19: 100, 1979.

    Google Scholar 

  158. R. A. Winkle, J. L. Anderson, F. Peter, P. J. Meffin, R. E. Fowler, D. C. Harrison: The hemodynamic effects of intravenous tocainide in patients with heart disease. Circ 57: 787, 1978.

    Google Scholar 

  159. R. L. Woosley, D. G. McDevitt, A. S. Nies, R. F. Smith, G. R. Wilkenson, J. A. Oates: Suppression of ventricular ectopic depolarizations by tocainide. Circ 56: 980, 1977.

    Google Scholar 

  160. P. J. Podrid, B. Lown: Tocainide for refractory symptomatic ventricular arrhythmias. Am J Cardiol 49: 1279, 1982.

    Google Scholar 

  161. L. N. Horowitz, M. R. Josephson, A. Farshidi: Human electrophysiology of tocainide, a lidocaine congener. Am J Cardiol 42: 276, 1980.

    Google Scholar 

  162. L. Ryden, K. Amman, T. B. Conradson, S. Hofuendahl, O. Mortenson, P. Smedgard: Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100: 1006, 1980.

    Google Scholar 

  163. R. A. Winkle, J. W. Mason, D. C. Harrison: Tocainide for drug resistant ventricular arrhythmias. Efficacy, side effects and lidocaine responsiveness for predicting tocainide success. Am Heart J 100: 1031, 1980.

    Google Scholar 

  164. S. H. Hohnloser, H. W. Lang, E. A. Raeder, P. J. Podrid, B. Lown: Short and long term tocainide therapy for malignant ventricular tachyarrhythmias. Circ 73: 143, 1986.

    Google Scholar 

  165. M. Hession, R. Blum, P. J. Podrid, B. Lown: Mexiletine and tocainide: Does response to one predict response to the other? J Am Coll Cardiol 7: 338, 1986.

    Google Scholar 

  166. H. R. Horn, Z. Hadidian, J. L. Johnson, H. G. Vassalo, J. H. Williams, M. D. Young: Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J 100: 1037, 1980.

    Google Scholar 

  167. Lown (ed.) A Symposium: Ethmozine (moricizine HCI) — A new antiarrhythmic agent. Am J Cardiol 60:suppl F, 1987.

    Google Scholar 

  168. Z. P. Senova, M. V. L’Vov: Mechanism of the antiarrhythmic effect of ethmozine. Farmakol Toksikol 36: 703, 1973.

    Google Scholar 

  169. L. V. Rosenshtraukh, E. P. Anyukhovsky, V. V. Nesterenko, A. L. Undrovinas, K. K. Shugushev, V. F. Portnoy, N. A. Burnshev: Electrophysiologic aspects of moricizine HCL. Am J Cardio 60: 27F, 1987.

    Google Scholar 

  170. A. S. Smitnev, K. K. Shugushi, L. V. Rosenshtraukh: Clinical electrophysiologic and antiarrhythmic efficacy of moricizine ECL. Am J Cardiol 60: 40F, 1987.

    Google Scholar 

  171. C. R. C. Wyndham, C. M. Pratt, D. E. Mann, V. F. Runova: Electrophysiology of ethmozine (moricizine HCL) for ventricular tachycardia. Am J Cardiol 60: 67F, 1987.

    Google Scholar 

  172. N. V. Kaverina, Z. P. Senova, V. S. Mitrophanrv, G. McMahon, J. O. Humphries, D. T. Mason, R. L. Williams: Pharmacology of ethmozin: a new antiarrhythmic drug Farmacol Toksikol 22: 182, 1972.

    Google Scholar 

  173. R. L. Woosley, J. Morganroth, R. N. Fogoros, et al.: Pharmacokinetics of moricizine HCL. Am J Cardiol 60: 35F, 1987.

    Google Scholar 

  174. H. L. Kennedy, A. J. J. Wood, R. T. MacFarland: Drug interactions with ethmozine (moricizine HCL). Am J Cardiol 60: 79F, 1987.

    Google Scholar 

  175. C. M. Pratt, P. J. Podrid, A. A. Seals, J. B. Young, M. Hession, S. Lampert, M. Quiones, B. Lown: Effect of ethmozine (moricizine HCL) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments. Am J Cardiol 60: 73F, 1987.

    Google Scholar 

  176. P. J. Podrid, A. Lyakishev, B. Lown, N. Mazur: Ethmozine, a new antiarrhythmic drug for suppressing ventricular premature complexes. Circ 61: 450, 1980.

    Google Scholar 

  177. S. N. Singh, R. DiBianco, J. S. Gottdiener: Effects of moricizine hydrochloride in inducing high frequency ventricular arrhythmia: Results of a prospective, controlled trial. Am J Cardiol 53: 745, 1984.

    Google Scholar 

  178. C. M. Pratt, J. B. Young, M. J. Francis, A. A. Taylor, H. J. Norton, L. English, D. E. Mann, H. Kopelen, M. A. Quiones, R. Roberts: Comparative efficacy of disopryramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo controlled longitudinal crossover design. Circ 69: 288, 1984.

    Google Scholar 

  179. M. J. Hession, S. Lampert, P. J. Podrid, B. Lown: Ethmozine (moricizine HCL) therapy for complex ventricular arrhythmias. Am J Cardiol 60: 59F, 1987.

    Google Scholar 

  180. J. Morganroth, C. M. Pratt, H. L. Kennedy: Efficacy and tolerance of ethmozine (moricizine HCL) in placebo controlled trials. Am J Cardiol 60: 48F, 1987.

    Google Scholar 

  181. J. L. Bergey, T. Salkowsk, D. R. Mirch: Antiarrhythmic, hemodynamic and cardiac electrophysiologic evaluation of N-(2,6-dimethyphenyl)-N’[3(1-methylithylamino)-propyll urea (wy-42, 362) Arznlim Forschung 33: 1258, 1983.

    Google Scholar 

  182. J. J. Colatsky, C. B. Bird, J. A. Knowles: Cardiac electrophysiology of the antiarrhythmic agent, recainam (Wy 42, 362) in anesthetized dogs: Relation to plasma and myocardial concentrations. J Cardiovasc Pharmacol 11: 308, 1988.

    Google Scholar 

  183. R. Takikawa, K. Kamiya, R. Kato, B. N. Singh: Electrophysiologic effects of a new antiarrhythmic agent, recainam, in isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 11: 875, 1988.

    Google Scholar 

  184. R. M. Luceri, A. Castellanos, L. Zaman: Efficacy and safety of intravenous Wy-42, 362, a new antiarrhythmic agent for ventricular arrhythmias (abstr.). Clin Res 32: 244A, 1984.

    Google Scholar 

  185. M. I. Anastasiou-Nana, J. L. Anderson, E. M. Hampton, J. N. Nanas, B. M. Heath: Recainam, a potent new antiarrhythmic agent: effects in complex ventricular arrhythmias. J Am Coll Cardiol 8: 427, 1986.

    Google Scholar 

  186. R. M. Luceri, T. Selby, S. F. Sesenwine, A. Castellanos, L. Zamon: Pharmacokinetics and safety of a new type 1 antiarrhythmic agent (abstr.). Clin Res 33: 285A, 1985.

    Google Scholar 

  187. J. L. Anderson, M. I. Anastasiou-Nana, B. M. Heath, R. L. MenCove, J. N. Nanas, J. Freedman: Efficacy of recainam, a new antiarrhythmic drug for control of ventricular arrhythmia. Am J Cardiol 60: 281, 1987.

    Google Scholar 

  188. B. N. Singh, P. Deedwania, K. Nademanee, A. Ward, E. M. Sorkin: Sotalol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34: 311, 1987.

    Google Scholar 

  189. B. N. Singh, E. M. Vaughan-Williams: A third class of antiarrhythmic action: effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle of MJI 999 and AM 3676. Br J Pharmacol 39: 675, 1970.

    Google Scholar 

  190. T. Wang, R. M. Bergstrand, K. A. Thompson, L. A. Siddoway, H. J. Duff, R. L. Woosley, D. M. Roden: Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 57: 1160, 1986.

    Google Scholar 

  191. R. Kato, S. Yabeic, N. Ikeda, R. Kannan, B. N. Singh: Electrophysiologic effects of dextro and levo isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 7: 1 16, 1980.

    Google Scholar 

  192. J. M. McComb, B. McGovern, J. B. McGowan, J. N. Ruskin, H. Garan: Electrophysiologic effects of d-sotalol in humans. J Am Coll Cardiol 10: 211, 1987.

    Google Scholar 

  193. P. Touboul, G. Atallah, G. Kirkorian, M. Lamaud, P. Moleur: Clinical electrophysiology of intravenous sotalol, a beta blocking drug with class III antiarrhythmic properties. Am Heart J 107: 888, 1984.

    Google Scholar 

  194. B. N. Singh, K. Nademanee: Sotalol: A beta blocker with unique antiarrhythmic properties. Am Heart J 114: 121, 1987.

    Google Scholar 

  195. M. Anttila, M. Arstila, M. Pfeffer, R. Tikkanen, V. Vallinkoski: Human pharmacokinetics of sotalol. Acta Pharmacologica et toxicologica 39: 118, 1976.

    Google Scholar 

  196. H. K. Sudquist, M. Anttila, J. Forrstrom, A. Kasenan: Serum levels and half-life of sotalol in chronic renal failure. Ann Clin Res 7: 442, 1975.

    Google Scholar 

  197. J. M. Cruickshank: The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100: 160, 1980.

    Google Scholar 

  198. K. Schnelle, G. Klein, A. Schinz: Studies on the pharmacokinetics and pharmacodynamics of beta-adrenergic blocking agent sotalol in normal man. J Clin Pharmacol 19: 516, 1979.

    Google Scholar 

  199. H. Brooks, J. Banas, S. Meister, M. Szues, J. Dalen, L. Dexter, Sotalol — induced beta blockade in cardiac patients. Circ 42: 99, 1970.

    Google Scholar 

  200. I. Hutton, A. R. Lorimar, W. S. Millis, D. McCall, J. M. Reid, T. V. D. Lawrie: Hemodynamics and myocardial function after sotalol. Br Heart J 34: 787, 1972.

    Google Scholar 

  201. J. J. Mahmarian, M. S. Verani, T. Hohmann, R. Hill, B. C. Thornton, R. Bolli, J. B. Young, R. Roberts, C. M. Pratt: The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography. Circ 76: 324, 1987.

    Google Scholar 

  202. K. K. Teo, M. Harlem, J. H. Horgan: Sotalol infusion in the treatment of supraventricular tachyarrhythmias. Chest 87: 113, 1985.

    Google Scholar 

  203. I. Rizos, J. Senges, R. Javernig, W. Lengfelder, E. Czygan, J. Brachmann, W. Kubler: Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. Am J Cardiol 53: 1022, 1984.

    Google Scholar 

  204. T. J. Campbell, T. P. Gavaghan, J. J. Morgan: Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a randomized trial. Br Heart J 54: 86, 1985.

    Google Scholar 

  205. J. H. Janssen: Prevention and treatment of supraventricular tachycardia early following coronary artery bypass surgery. Angiology 36: 575, 1985.

    Google Scholar 

  206. P. Tuboul, G. Atallah, G. Krkorian, P. Lavaud, M. P. Mathieu, A. Dellinger: Effects of intravenous sotalol in patients with atrioventricular accessory pathways. Am Heart J 114: 545, 1987.

    Google Scholar 

  207. K. P. Kunze, M. Schluter, K. H. Kuck: Sotalol in patients with Wolff-Parkinson-White Syndrome. Circ 75: 1050, 1987.

    Google Scholar 

  208. L. B. Mitchell, D. G. Wyse, H. J. Duff: Electropharmacology of sotalol in patients with Wolff-Parkinson-White Syndrome. Circ 76: 810, 1987.

    Google Scholar 

  209. D. I. Sahar, J. A. Reiffel, J. T. Bigger, A. Squatrito, G. A. Kidwell: Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. Am Heart J 117: 562, 1989.

    Google Scholar 

  210. D. P. Myburgh, A. P. Goldman, J. Cartoon, J. M. Schamroth: The efficacy of sotalol in suppressing ventricular ectopic beats. S Afr Med J 56: 295, 1979.

    Google Scholar 

  211. D. Burckhardt, M. Pfisterer, A. Hoffmann, F. Burkart, H. Emmeregger, M. Jost, P. Bolli, F. R. Buehler: Effects of the beta-adrenoceptor blocking agent sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. Cardiol 70: 114, 1983.

    Google Scholar 

  212. J. L. Anderson, J. C. Askins, E. M. Gilbert, R. H. Miller, D. L. Keefe, J. C. Somberg, R. A. Freedman, L. R. Haft, J. W. Mason, J. N. Lessem: Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. J Am Coll Cardiol 8: 752, 1986.

    Google Scholar 

  213. L. J. Jordaens, D. L. Palmer Am Clement: Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. Eur Heart J 10: 218, 1989.

    Google Scholar 

  214. M. A. Ruder, T. Ellis, C. Lebsack, R. M. Mead, N. A. Smith, R. A. Winkle: Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. J Am Coll Cardiol 13: 145, 1989.

    Google Scholar 

  215. R. Gonzales, M. M. Scheinman, J. M. Herre, J. C. Griffin, M. J. Sauve, H. Sharkey: Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 12: 1568, 1988.

    Google Scholar 

  216. M. A. Kopelman, L. Woosley, J. T. Lee, D. M. Roden, D. S. Echt: Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 61: 1006, 1988.

    Google Scholar 

  217. J. Schwartz, K. Crocker, J. Wynn, J. C. Somberg: The antiarrhythmic effects of d-sotalol. Am Heart J 114: 539, 1987.

    Google Scholar 

  218. H. D. Gossinger, P. Siostrzonek, R. Schmoliner, G. Grimm, U. Jager, H. Mosslacher: Sotalol-induced torsades des pointes in a patient with pre-existent normal response to programmed stimulation. Eur Heart J 8: 1351, 1987.

    Google Scholar 

  219. K. H. Kuck, K. P. Kunze, W. Bleifeld: Sotalol-induced torsade de pointes. Am Heart J 107: 179, 1984.

    Google Scholar 

  220. M. Laakso, I. Arvala, S. Tervonen, M. Sotaravta: Retroperitoneal fibrosis associated with sotalol. Br Med J 285: 1085, 1982.

    Google Scholar 

  221. B. N. Singh, D. P. Zipes (Ed.): Proceedings of the symposium — Amiodarone: Basic concepts and clinical applications. Am Heart J 106:787, 1983.

    Google Scholar 

  222. D. P. Zipes, E. N. Prystowsky, J. J. Heger: Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol 3: 1059, 1984.

    Google Scholar 

  223. N. Groupil, J. Lenfant: The effects of amiodarone on the sinus node activity of the rabbit heart. Eur J Pharmacol 39: 23, 1976.

    Google Scholar 

  224. W. F. Lubbe, M. L. McFadyen, C. A. Muller, M. Worthington, L. M. Opie: Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart. Am J Cardiol 43: 533, 1979.

    Google Scholar 

  225. B. N. Singh: Amiodarone: historical development and pharmacologic profile. Am Heart J 106: 788, 1983.

    Google Scholar 

  226. J. W. Mason: Drug therapy: amiodarone. N Eng J Med 316: 455, 1987.

    Google Scholar 

  227. D. W. Holt, G. T. Tucker, P. R. Jackson, G. C. A. Storey: Amiodarone: pharmacokinetics. Am Heart J 106: 840, 1983.

    Google Scholar 

  228. P. C. Adams, D. W. Holt, C. A. Storey, A. R. Morley, J. Callaghan, W. F. Campbell: Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circ 72: 1064, 1985.

    Google Scholar 

  229. D. W. Holt, G. T. Tucker, A. C. Jackson, G. C. A. Storey: Amiodarone pharmacokinetics. Am Heart J 106: 840, 1983.

    Google Scholar 

  230. A. Berdeauz, A. Roche, T. Labaille, B. Giroux, A. Edovard, J. F. Giudicelli. Tissue extraction of amiodarone and N-desethylamiodarone in man after a single oral dose. Br J Clin Pharmacol 18: 759, 1984.

    Google Scholar 

  231. L. A. Siddoway, C. B. McAllister, G. R. Wilkinson, D. M. Roden, R. L. Woosley: Amiodarone dosing: a proposal based upon its pharmacokinetics. Am Heart J 106: 951, 1983.

    Google Scholar 

  232. F. Andreasen, H. Agerback, P. Bjerregaard, H. Gotzsche: Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 19: 293, 1981.

    Google Scholar 

  233. J. J. Heger, E. N. Prystowsky, D. P. Zipes: Relationships between amiodarone dosage, drug concentrations and adverse side effects. Am Heart J 106: 931, 1983.

    Google Scholar 

  234. M. M. Rotmensch, B. Belhassen, B. N. Swanson, D. Shoshani, S. R. Spielman, A. J. Greenspan, A. M. Greenspan, P. H. Vlasses, L. N. Horowitz: Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Int Med 101: 462, 1984.

    Google Scholar 

  235. I. Helmy, J. M. Serre, G. Gee, H. Sharkey, P. Malone, M. J. Sauve, J. C. Griffin, M. M. Scheinman: Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol 12: 1015, 1988.

    Google Scholar 

  236. F. I. Marcus: Drug interactions with amiodarone. Am Heart J 106: 924, 1983.

    Google Scholar 

  237. E. J. Kozinski, J. B. Albin, E. Young, S. M. Lewis, S. LeLand Jr.: Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 4: 565, 1984.

    Google Scholar 

  238. C. T. Haffajie, J. C. Love, J. S. Alpert, G. K. Asdourian, K. C. Sloan: Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: Dosage experience. Am Heart J 106: 935, 1983.

    Google Scholar 

  239. M. B. Rosenbaum, P. A. Chiale, M. S. Halpern, G. J. Nau, J. Przybylski, R. J. Levi, J. O Lazzari, M. V. Elizari: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38: 934, 1976.

    Google Scholar 

  240. P. J. Podrid, B. Lown: Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachycarrhythmias. Am Heart J 101: 374, 1981.

    Google Scholar 

  241. E. P. Veltri, P. R. Reid, E. V. Platia, L. S. C. Griffith: Amiodarone in the treatment of life-threatening ventricular tachycardia: The role of Holter monitoring in predicting long-term clinical efficacy. Am Coll Cardiol 6: 806, 1985.

    Google Scholar 

  242. R. N. Fogoros, K. P. Anderson, R. A. Winkle, C. D. Swerdlow, J. W. Mason: Amiodarone: clinical efficacy and toxicity in 96 patients with reccurrent, drug-refractory arrhythmias. Circ 68: 88, 1983.

    Google Scholar 

  243. T. Peter, A. Hamer, W. J. Mandel, D. Weiss: Evaluation of amiodarone therapy in the treatment of drug resistant cardiac arrhythmias: long-term follow-up. Am Heart J 106: 943, 1983.

    Google Scholar 

  244. C. I. Haffajee, J. C. Love, A. T. Canada, L. J. Lesko, G. Asdourian, J. S. Alpert: Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circ 67: 1347, 1983.

    Google Scholar 

  245. W. J. McKenna, C. M. Oakley, D. M. Krikler, J. F. Goodwin: Improved survival with amiodarone in patients with hyperthrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53: 412, 1985.

    Google Scholar 

  246. J. J. Heger, E. N. Prystowsky, W. M. Jackman, G. V. Naccarelli, K. A. Warfel, R. L. Rinkenberger, D. P. Zipes: Amiodarone: clinical efficacy and electrophysiology during long-term therapy for reccurent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305: 539, 1981.

    Google Scholar 

  247. H. L. Waxman, W. C. Groh, F. E. Marchlinski, A. E. Buxton, L. M. Sadowski, L. N. Horowitz, M. E. Josephson, J. A. Kaster: Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effect in 51 patients. Am J Cardiol 50: 1066, 1982.

    Google Scholar 

  248. G. C. Nademanee, J. A. Hendrickson, D. S. Cannon, B. N. Goldreyer, B. N. Singh: Control of refractory life-threatening ventricular arrhythmias by amiodarone. Am Heart J 101: 759, 1981.

    Google Scholar 

  249. B. McGovern, G. Garan, R. F. Malacoff: Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53: 1558, 1984.

    Google Scholar 

  250. G. V. Naccarelli, N. S. Fineberg, D. P. Zipes, J. J. Heger, G. Duncan, E. N. Prystowsky. Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 6: 814, 1985.

    Google Scholar 

  251. A. Kadish, F. E. Marchlinski, M. E. Josephson, A. E. Buxton. Amiodarone: Correlation of early and late electrophysiologic studies with outcome. Am Heart J 112: 1 134, 1986.

    Google Scholar 

  252. L. N. Horowitz, A. M. Greenspan, S. R. Spielman, C. R. Webb, J. Morganroth, H. Rotmensch, N. M. Sokoloff, A. P. Rae, B. L. Segal, H. R. Kay: Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary artery disease. Am J Cardiol 55: 367, 1985.

    Google Scholar 

  253. P. J. Podrid: Practical follow-up guidelines for patients treated with amiodarone: Clin Cardiol 10 (suppl 1): 107, 1987.

    Google Scholar 

  254. E. Rowland, D. M. Krikler: Electrophysiological assessment of amiodarone in the treatment in patients with resistant paroxysmal tachycardias. Br Heart J 44: 82, 1980.

    Google Scholar 

  255. D. E. Ward, A. J. Camm, R. A. J. Spurrell: Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J 44: 91, 1980.

    Google Scholar 

  256. T. B. Graboys, P. J. Podrid., B. Lown: The efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 106: 870, 1983.

    Google Scholar 

  257. H. J. J. Wellens, P. Brugada, H. Abdollah: Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White Syndrome. Am Heart J 106: 876, 1983.

    Google Scholar 

  258. E. A. Raeder, P. J. Podrid, B. Lown: Side effects and complications of amiodarone therapy. Am Heart J 109: 975, 1985.

    Google Scholar 

  259. L. Harris, W. J. McKenna, E. Roland, D. M. Krikler: Side effects and possible contraindications of amiodarone use. Am Heart J 106: 916, 1983.

    Google Scholar 

  260. F. Morady, M. J. Sauve, P. Malone, E. N. Shen, A. B. Schwartz, A. Bhandari, E. Keung, R. J. Sung, M. M. Scheinman: Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 58: 975, 1983.

    Google Scholar 

  261. S. Sclarovsky, R. F. Lewin, O. Kracoff, B. Strasberg, A. Arditti, J. Agman: Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 105: 6, 1983.

    Google Scholar 

  262. B. McGovern, H. Garan, E. Kelly, J. N. Ruskin: Adverse reactions during treatment with amiodarone. Br Med J 287: 175, 1983.

    Google Scholar 

  263. C. Maro, T. Romero, M. A. Lorris-Peiretti: Amiodarone and hypokalemia: a dangerous combination. Int J Cardiol 13: 356, 1986.

    Google Scholar 

  264. W. J. Marin, E. D. Rosenow: Amiodarone pulmonary toxicity: recognition and pathogenesis (part 1 and 2). Chest 93:1067 and 1242, 1988.

    Google Scholar 

  265. L. Rakita, S. M. Sobol, N. Mostow, T. Vrobel: Amiodarone pulmonary toxicity. Am Heart J 106: 906, 1983.

    Google Scholar 

  266. F. E. Marchlinski, T. S. Gansler, H. L. Waxman, M. E. Josephson: Amiodarone pulmonary toxicity. Ann Int Med 97: 839, 1982.

    Google Scholar 

  267. B. N. Singh, K. Nademanee: Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am Heart J 106: 857, 1983.

    Google Scholar 

  268. D. V. Ingram: Ocular effects in long-term amiodarone therapy. Am Heart J 106: 902, 1983.

    Google Scholar 

  269. H. Just (Ed.), A symposium: Pirminol — a unique, new antiarrhythmic agent. Am J Cardiol 59 (suppl H), 1987.

    Google Scholar 

  270. R. F. Reder, P. Danil, M. R. Rosen: Effects of pirmenol HCL on electrophysiologic properties of cardiac Purkinje fibers. Eur J Pharmacol 61: 321, 1980.

    Google Scholar 

  271. I. D. Dukes, E. M. Vaughan Williams, P. D. Dennis: Electrophysiological and cardiovascular effects of pirmenol, a new class l antiarrhythmic drug. J Cardiovasc Pharmacol 8: 227, 1986.

    Google Scholar 

  272. H. Nakaya, N. Tohse, M. Kanno: Frequency and voltage dependent depression of maximum upstroke velocity of action potentials by pirmenol in guinea pig ventricular muscles. Jap J Pharmacol 48: 423, 1988.

    Google Scholar 

  273. H. Kotaki, S. Hiai, T. Kinugaua, I. Ito, J. Yamasaki, J. Hasigawa, H. Masheba: Effects of pirmenol hydrochloride in the spontaneous action potentials and membrane current systems of rabbit sinoatrial node cells. J Electrocardiol 21: 355, 1988.

    Google Scholar 

  274. L. B. Liem, D. A. Clay, M. C. Franz, C. D. Swendlow: Electrophysiology and antiarrhythmic efficacy of intravenous pirmenol in patients with sustained ventricular tachyarrhythmias. Am Heart J 113: 1390, 1987.

    Google Scholar 

  275. M. J. Reiter, S. C. Hammill, D. G. Shand, C. Verghese, E. McCarthy, E. L. Pritchett. Efficacy, safety and pharmacokinetics of a concentration maintaining regimen of intravenous pirmenol. Am J Cardiol 52: 83, 1983.

    Google Scholar 

  276. M. deBuitleir, B. J. Grevey, T. Johnson, W. H. Kou, S. D. Nelson, S. Schmaltz, F. Morady: Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations. Am Heart J 116: 379, 1988.

    Google Scholar 

  277. J. L. Anderson, J. R. Lutz, J. M. Nappi: Pirmenol for control of ventricular arrhythmias, oral dose ranging and short-term maintenance study. Am J Cardiol 53: 522, 1984.

    Google Scholar 

  278. J. Baguena Candela: for the Pirmenol Multicenter Study Group. Effectiveness of pirmenol hydrochloride in suppressing high frequency ventricular ectopy: a placebo controlled, double blind multicenter study. Am J Cardiol 59: 48H, 1987.

    Google Scholar 

  279. T. G. Lee, A. D. Goldberg, T. Chang, M. T. Jerkland, G. J. Yakatan, E. L. Johnson, J. G. Toole, S. Goldstien: Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia. J Cardiovasc Pharmacol 5: 632, 1983.

    Google Scholar 

  280. S. C. Hammill, D. G. Shand, F. E. Harrell, J. M. Zimmerman, M. J. Reiter, C. Verghese, E. L. Pritchett: Pirmenol Kinetics and effective oral dose. Clin Pharmacol Ther 32: 686, 1982.

    Google Scholar 

  281. K. A. Ellenbogin, S. F. Roark, A. L. Sintetos, M. S. Smith, E. A. McCarthy, W. M. Smith, R. E. Kates, E. L. Pritchett: Pharmacodynamics of oral pirmenol Clin Pharm Ther 42: 405, 1987.

    Google Scholar 

  282. D. C. Garg, N. S. Jallad, S. Singh, K. F. Ng, D. J. Weidler: Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug. J Clin Pharm 28: 812, 1988.

    Google Scholar 

  283. T. Chang: Preclinical and clinical pharmacokinetics of pirmenol. Am J Cardiol 59: 15H, 1987.

    Google Scholar 

  284. K. A. Stringer, A. B. Cetnarowski, A. Goldfarb, M. E. Lebsack, T. Chang, A. J. Sidman: Enhanced pirmenol elimination by refampin. J Clin Pharm 28: 1094, 1988.

    Google Scholar 

  285. K. G. Morris, H. R. Philipp: Hemodynamic effects of intravenous pirmenol. Angiol 39: 321, 1988.

    Google Scholar 

  286. L. K. Toivonen, M. S. Nieminen: Hemodynamic effects of pirmenol, a new antiarrhyhmic agent, assessed noninvasively. Int J Cardiol 10: 111, 1986.

    Google Scholar 

  287. L. K. Toivonen, M. S. Nieminen, V. Manninen, H. Frick: Conversion of paroxysmal atrial fibrillation to sinus rhythm by intravenous pirmenol. Am J Cardiol 59: 39H, 1987.

    Google Scholar 

  288. L. K. Toivonen: Effect of pirmenol on premature atrial contractures. Ann Clin Res 18: 106, 1986.

    Google Scholar 

  289. L. K. Toivonen: Pirmenol in termination of paroxysmal supraventricular tachycardia. Clin Cardiol 9: 369, 1986.

    Google Scholar 

  290. J. E. Brown, R. Yee, G. J. Klein: Acute electrophysiologic effects of pirmenol in normal subjects and in patients with Wolff Parkinson White syndrome. Am J Cardiol 57: 775, 1986.

    Google Scholar 

  291. A. Buitleir, M. Crevey B., T. Johnson, J. B.erman, F. Morady: Efficacy of oral pirmenol in suppressing ventricular premature depolarization. Ir Med J 80: 60, 1987.

    Google Scholar 

  292. D. J. Farnham: A multicenter dose response study of pirmenol hydrochloride in patients with ventricular premature contractions. Am J Cardiol 59: 43H, 1987.

    Google Scholar 

  293. E. M. Hampton, J. L. Anderson, T. R. Lutz, J. M. Nappi: Initial and longterm outpatient experience with pirmenol for control of ventricular arrhythmias. Eur J Clin Pharmacol 31: 15, 1986.

    Google Scholar 

  294. A. R. Easley, D. E. Mann, M. J. Reiter, M. J. Sakun, S. M. Sullivan, S. A. Magro, J. C. Luck, C. R. Wgndham. Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 58: 86, 1986.

    Google Scholar 

  295. B. F. Johnson, V. Shekar, T. Woodman, A. T. Canada: Salivary concentrations of pirmenol as a possible cause of unpleasant taste. Br J Clin Pharmacol 22: 613, 1986.

    Google Scholar 

  296. S. H. Hamill, D. G. Shand. P. A. Routledge, M. C. Hendman, J. T. Baker, E. L. Pritchett: Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. 65: 369, 1982.

    Google Scholar 

  297. M. C. Hendman, J. T. Baker, E. L. Pritchett: Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. Circ 65: 369, 1982.

    Google Scholar 

  298. P. Alboni, R. Cappato, N. Paparella, R. Pirani, G. C. Candini, A. M. Tomcesi: Electrophysiologic effects and mechanisms of action of oral quinidine in patiens with sinus bradycardia and first degree AV block. Eur Heart J 8: 1080, 1987.

    Google Scholar 

  299. P. G. Schmid, L. D. Nelson, A. C. Mark, D. D. Heistad, F. M. Abboud: Inhibition of adrenergic vasoconstriction by quinidine. J Pharmacol Exp Ther 188: 124, 1974.

    Google Scholar 

  300. J. W. Mason, R. A. Winkle, A. K. Reder, E. B. Stenson, D. C. Harrison: The electrophysiologic effects of quinidine in the transplanted human heart. J Clin Invest 59: 481, 1977.

    Google Scholar 

  301. F. M. Weld, J. Coronilas, J. N. Rottmann, J. T. Bigger: Mechanism of quinidine induced depression of maximum upstroke velocity in ovine cardiac Purkinje fibers. Circ Res 50: 369, 1982.

    Google Scholar 

  302. B. F. Hoffman, M. R. Rosen, A. L. Wit: Electrophysiology and pharmacology of cardiac arrhythmias. VII Cardiac effects of quinidine and procainamide. Am Heart F 89: 804, 1975.

    Google Scholar 

  303. M. E. Josephson, S. F. Seides, W. P. Botsford, G. M. Weisfogel, M. Akhtar, A. R. Caracta, S. H. Lau, A. N. Damato: The electrophysiologic effects of intramuscular quinidine in the atrioventricular conducting system in man. Am Heart J 87: 55, 1974.

    Google Scholar 

  304. Y. Watanabe, L. S. Dreifres: Interactions of quinidine and potassium in atrioventricular transmission. Circ Res 20: 434, 1967.

    Google Scholar 

  305. L. M. Hondegham, A. D. Grant, R. A. Jensen: Antiarrhythmic drug action. Selective depression of Hypoxic Cardiac cells. Am Heart J 87: 602, 1974.

    Google Scholar 

  306. T. Colatsky: Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. Circ Res 50: 17, 1982.

    Google Scholar 

  307. C. M. Hodeghem: Effects of lidocaine, phenytoin and quinidine in the ischemic canine myocardium. J Electrocardiol 9: 203, 1976.

    Google Scholar 

  308. R. H. Heisenbuttel, J. T. Bigger: The effect of oral quinidine in intraventricular conduction in man. Correlation of plasma quinidine with changes in QRS duration. Am Heart J 80: 453, 1970.

    Google Scholar 

  309. C. D. Swerdlow, J. O. Yu, E. Jacobson, S. Mann, R. A. Winkle, J. C. Griffen, D. L. Ross, J. W. Mason: Safety and efficacy of intravenous quinidine. Am J Med 75: 36, 1983.

    Google Scholar 

  310. D. J. Greenblatt, H. J. Pfeifer, H. R. Ochs, K. Franke, P. S. MacLaughlin, T. W. Smith, J. Koch-Weser: Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharm Exp Ther 202: 365, 1977.

    Google Scholar 

  311. K. A. Conrad, B. L. Moch, L. A. Chidsey: Pharmacokinetic studies of patients with arrhythmias. Circ 55: 1, 1977.

    Google Scholar 

  312. K. H. Palmer, B. Marten, B. Baggett, M. E. Wall: The metabolic fate of orally administered quinidine gluconate in humans. Brochen Pharmacol 18: 1845, 1969.

    Google Scholar 

  313. B. B. Brodie, J. E. Baer, L. C. Craig: Metabolic products in anchona alkaloids in human urine. J Biol Chem 188: 567, 1951.

    Google Scholar 

  314. D. E. Drayer, D. T. Lowenthal, K. M. Restivo, A. Schwartz, C. E. Look, M. M. Reidenberg: Steady state levels of quinidine active metabolites in cardiac patients with varying degress of renal function. Clin Pharm Ther 24: 31, 1978.

    Google Scholar 

  315. K. M. Kessler, D. T. Lowenthal, H. Warner, T. Gibson, W. Briggs, M. M. Reidenberg: Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 290: 70, 1974.

    Google Scholar 

  316. H. L. Lonn, R. J. Luchi: Some quantitative aspects of the binding of quinidine and related quinoline compounds by human serum albumin. J Clin Invest 40: 509, 1961.

    Google Scholar 

  317. J. Bellet, G. Hamden, A. Somlyo, R. Lara: The reversal of cardiotoxic effects of quinidine by molar sodium lactate. An experimental study. Am J Med Sci 237: 165, 1959.

    Google Scholar 

  318. E. B. Leahey, J. A. Reiffel, R. H. Heissinbuttel, R. E. Drusin, W. P. Lovejoy, T. B. Bigger: Enhanced cardiac effect of digoxin during quinidine treatment. Arch Int Med 139: 519, 1979.

    Google Scholar 

  319. G. G. Belz, P. E. Aust, W. Doering, M. Heinz, B. Schneider: Pharmacodynamics of a single dose of quinidine during chronic digoxin treatment. Eur J Clin Pharmacol 22: 117, 1982.

    Google Scholar 

  320. N. J. warner, E. B. Leahey, T. J. Hougan, J. T. Bigger, T. W. Smith: Tissue digoxin concentrations during the quinidine digoxin interaction. Am J Cardiol 51: 1717, 1983.

    Google Scholar 

  321. J. L. Data, G. R. Wilkinson, A. S. Nies: Interaction of quinidine with anticonvulsant drugs. N Engl J Med 244: 699, 1976.

    Google Scholar 

  322. J. Koch-Weser: Quinidine induced hypoprothombanemic hemorrhage in patients in chronic warfarin therapy. Ann Int Med 68: 511, 1968.

    Google Scholar 

  323. E. T. Angelakos, E. P. Hastings: The influence of quinidine and procainamide on myocardial contractility in vivo. Am J Cardiol 6: 761, 1960.

    Google Scholar 

  324. W. R. Markiowicz, R. Winkle, G. Binitti, R. Kernoff, D. C. Harrison: Normal myocardial contracticity state in the presence of quinidine. Circ 53: 101, 1976.

    Google Scholar 

  325. R. A. O’Rourke, L. D. Horowitz: Effects of chronic oral quinidine on left ventricular performance. Am Heart J 101: 769, 1981.

    Google Scholar 

  326. D. White, M. Crawford, R. O’Rourke, J. Karliner, J. Gorwit: Effects of quinidine in left ventricular performance in normals and patients with congestive cardiomyopathy. Circ 56 (Suppl III): 180, 1977.

    Google Scholar 

  327. T. Sodermark, B. Johnson, A. Olsson, L. Oro, H. Wallin, V. Edhag, A. Sjorgren, M. Danielsson, G. Rosenhamer: Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation in flutter. Bri Heart J 37: 486, 1975.

    Google Scholar 

  328. K. Rasmussen, H. Wang, D. Fausa: Comparative efficacy of quinidine and verapamil in the maintenance of sinus rhythm after DC cardioversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand 645 (suppl): 23, 1981.

    Google Scholar 

  329. D. Wu, J. S. Hung, C. T. Kuo, K. S. Hsu, W. B. Shieh: Effects of quinidine on atrioventricular nodal reentrant paroxysmal tachycardia. Circ 64: 823, 1981.

    Google Scholar 

  330. T. D. Sillers, R. W. F. Campbell, T. M. Bashore, J. J. Gallagher: Effects of procainamide and quinidine sulfate in the Wolff Parkinson White syndrome. Circ 55: 15, 1977.

    Google Scholar 

  331. J. Morganroth, for the Mexiletine-Quinidine Research Group: Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. Am J Cardiol 60: 1276, 1987.

    Google Scholar 

  332. J. Morganroth, J. C. Somberg, P. E. Pool, P. H. Hsu, I. K. Lee, J. Purkee: Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol 7: 9, 1986.

    Google Scholar 

  333. M. Hodges: Role of propafenone in the treatment of ventricular premature beats. J Electrophysiol 1: 536, 1987.

    Google Scholar 

  334. J. Morganroth, H. Heinter: Comparative efficacy and safety of short acting and sustained release quinidine in the treatment of patients with ventricular arrhythmia. Am Heart J 110: 1176, 1985.

    Google Scholar 

  335. H. J. Duff, D. M. Roden, R. K. Primm, J. A. Oates, R. E. Woosley: Mexiletine in treatment of resistant ventricular arrhythmia enhancement of efficacy and dose related side effects by combination with quinidine. Circ 67: 1124, 1983.

    Google Scholar 

  336. J. P. DiMarco, H. Garan, J. N. Ruskin: Quinidine for ventricular arrhyth- mia. Value of electrophysiologic testing. Am J Cardiol 51: 9, 1985.

    Google Scholar 

  337. V. Torres, D. Flowers, D. Miara, J. Sombeog: Intravenous quinidine by intermittent bolus for electrophysiologic studies in patients with ventricular tachycardia. Am Heart J 108: 1437, 1984.

    Google Scholar 

  338. A. H. Selzer, H. W. Wray: Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circ 30: 17, 1964.

    Google Scholar 

  339. R. W. Koster, H. J. J. Wellens: Quinidine induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 38: 519, 1976.

    Google Scholar 

  340. D. M. Roden, R. L. Woosley, K. Primm: Incidence of clinical features of the quinidine associated long QT syndrome. Implications for patient care. Am Heart J 111: 1088, 1986.

    Google Scholar 

  341. M. Sokolow, A. C. Edgar: Blood quinidine concentrations as a guide in the treatment of cardiac arrhythmias. Circ 1: 576, 1950.

    Google Scholar 

  342. I. S. Cohen, J. Hershel, S. I. Cohen: Adverse reactions to quinidine in hospitalized patients. Findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 20: 151, 1977.

    Google Scholar 

  343. W. H. Stinson, V. A. Mikusick: Felsrile reactions to quinidine. Am J Med Sci 221: 440, 1951.

    Google Scholar 

  344. R. F. Larson: The mechanism of quinidine purpura. Blood 8: 16, 1953.

    Google Scholar 

  345. J. S. Birkhead, E. M. Vaughan Williams: Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. Brit Heart J 39: 657, 1977.

    Google Scholar 

  346. T. Kus, B. I. Sasyniuk: Electrophysiologic actions of disopyramide phosphate in canine ventricular muscle and Purkinje fibers. Circ Res 37: 844, 1975.

    Google Scholar 

  347. A. Sekeya, E. M. Vaughan Williams: A comparison of the antifibrillatory actions and effects in intracellular cardiac potentials of pronethalol, disopyramide and quinidine. Brit J Pharmacol 21: 473, 1963.

    Google Scholar 

  348. B. I. Sasyniuk, T. Kus: Cellular electrophysiologic changes induced by disopyramide phosphate in normal and infarcted hearts. J Int Med Res 4 (Suppl I): 20, 1976.

    Google Scholar 

  349. P. Danilo, M. R. Rosen: Cardiac effects of disopyramide. Am Heart J 62: 53, 1976.

    Google Scholar 

  350. T. A. English, A. J. Camm: The direct electrophysiologic effects of disopyramide phosphate in the transplanted human heart. Circ 67: 38, 1983.

    Google Scholar 

  351. P. R. Wilkinson, J. Desai, J. Hollister, R. Gonzalez, J. A. Abbott, M. M. Scheinman: Electrophysiologic effects of disopyramide in patients with atrioventricular nodal dysfunction. Circ 66: 1211, 1982.

    Google Scholar 

  352. A. LaBarre, H. C. Strauss, M. M. Scheinman, A. G. Wallace: Electrophysiologic effects of disopyramide phosphate in sinus node function in patients with sinus node dysfunction. Circ 59: 226, 1979.

    Google Scholar 

  353. M. E. Josephson, A. R. Caracta, S. H. Law, J. J. Gallagher, A. N. Damato: Electrophysiologic evaluation of disopyramide in man. Am Heart J 86: 771, 1973.

    Google Scholar 

  354. J. M. Desai, M. M. Sheinman, R. W. Peters, J. O’Young: Electrophysiologic effects of disopyramide in patients with bundle branch block. Circ 59: 215, 1979.

    Google Scholar 

  355. C. R. Kerr, E. N. Prystowsky, W. M. Smith, C. Cook, J. J. Gallagher: Electrophysiologic effects of disopyramide phosphate in patients with Wolff Parkinson White syndrome. Circ 65: 869, 1982.

    Google Scholar 

  356. R. A. J. Spurrell, C. W. Thornburn, J. Camm, E. Sowton, D. C. Deuchar: Effects of disopyramide in electrophysiologic properties of specialized conduction system in man and in accessory atrioventricular pathway in Wolff Parkinson White syndrome. Br Heart J 37: 861, 1975.

    Google Scholar 

  357. A. Karim: The pharmakinetics of Norpace. Angiol 26: 85, 1975.

    Google Scholar 

  358. P. H. Hinderling, E. R. Garrett: Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm 4: 199, 1976.

    Google Scholar 

  359. L. A. Siddoway, J. T. Barbey, D. M. Roden, R. L. Woosley: Pharmacologic evaluation of standard and controlled release of disopyramide. Angiol 38: 184, 1987.

    Google Scholar 

  360. C. M. Shaw, J. H. Doherty, H. L. Waxman, M. E. Josephson: The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide. Angiol 38: 192, 1987.

    Google Scholar 

  361. D. B. Haughey, J. J. Lima: Influence of concentration dependent protein binding in serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. Biopharm Drug Dispos 4: 103, 1983.

    Google Scholar 

  362. J. M. Bryson, B. Whiting, J. R. Lawrence. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 6: 409, 1978.

    Google Scholar 

  363. J. Bonde, N. A. Graudal, L. E. Pedersan, S. Balsiv, H. R. Angelo, T. L. Svendsen, J. P. Kampmann: Kinetics of disopyramide in decreased hepatic function. Eur J Clin Pharmacol 31: 73, 1986.

    Google Scholar 

  364. R. P. Kapil, J. E. Axilson, E. L. Mansfield, D. J. Edwards, B. McErlane, M. A. Mason, D. Lalka, C. R. Kerr: Disopyramide pharmacokinetics and metabolism: effect of inducers. Brit J Clin Pharmacol 24: 781, 1987.

    Google Scholar 

  365. M. L. Aitio, L. Mansury, E. Tala, Haataja, O. Aitio: The effect of enzyme induction on the metabolism of dysopyramide in man. Brit J Clin Pharmacol 11: 279, 1981.

    Google Scholar 

  366. M. Burk, U. Peters: Dispyramide kinetics in renal impairment: determinants of interindividual variability. Clin Pharmacol Ther 34: 331, 1983.

    Google Scholar 

  367. M. J. Sevka, J. J. Matthews, C. H. Nightingale, M. W. Izard, A. Fieldman, M. S. Chow: Disopyramide hemodialysis and kinetics in patients requiring long term hemodialysis. Clin Pharmacol Ther 29: 322, 1981.

    Google Scholar 

  368. J. Braum, F. Sorgel, W. P. Grath, S. Oie: Bioavailability of disopyramide in normal volunteers using unbound concentrations. Eur J Clin Pharma-col 32: 625, 1987.

    Google Scholar 

  369. S. M. Bryson, J. R. Lawrence, W. H. Steele, B. C. Campbell, H. L. Elliott, D. J. Sumner: The influence of protein binding in disopyramide clearance. Eur J Clin Pharmacol 23: 453, 1982.

    Google Scholar 

  370. D. B. Haughey, L. J. Kraft, G. R. Matzke, W. F. Keane, C. F. Halstenson: Protein binding of disopyramide and elevated alpha-1 -acid glycoprotein concentration in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 5: 35, 1985.

    Google Scholar 

  371. H. Echizen, S. Sarma, W. Umeda, T. Ishizaki: Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome. Clin Pharmacol Ther 40: 274, 1986.

    Google Scholar 

  372. E. Haworth, A. K. Burroughs: Disopyramide and warfarin interaction. Br Med J 2: 866, 1977.

    Google Scholar 

  373. A. J. Leach, J. E. Brown, P. W. Armstrong: Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. Am J Med 68: 839, 1980.

    Google Scholar 

  374. R. DiBianco, J. S. Gottdiener, S. N. Singh, R. D. Fletcher: A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation. Angiol 38: 174, 1987.

    Google Scholar 

  375. P. P. Mather: Cardiovascular effects of new antiarrhythmic agent, disopyramide phosphate. Am Heart J 84: 764, 1972.

    Google Scholar 

  376. G. B. Jensen, B. Sigard, Uhrenholt: Circulatory effects of intravenous disopyramide in heart failure. J Int Med Res 4 (Suppl 1) 42, 1976.

    Google Scholar 

  377. P. J. Podrid, A. Schoenberger, B. Lown: Congestive hart failure caused by oral disopyramide. N Engl J Med 302: 694, 1980.

    Google Scholar 

  378. P. R. Kowey, P. L. Friedman, P. J. Podrid, J. Zeilonka, B. Lown, J. Wynne, B. L. Holman: Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. Am Heart J 104: 769, 1982.

    Google Scholar 

  379. J. S. Gottdiener, R. DiBianco, R. Bates, B. J. Sauerbrum, R. D. Fletcher: Effects of disopyramide on left ventricular function: assessment by radionuclide (ineangiography). Am J Cardiol 51: 1554, 1983.

    Google Scholar 

  380. M. Arif, J. C. Ladlaw, C. Oshrain, P. W. Willis, C. H. Nissin, D. J. McDermott, W. S. Smith, A. Karim, R. R. Wilson: A randomized, double blind, parallel group comparison of disopyramide phosphate and quinidine on patients with cardiac arrhythmias. Angiol 34: 39, 1983.

    Google Scholar 

  381. J. Camm, D. Ward, R. A. Spurrell: The effects of intravenous disopyramide phosphate in reentrant paroxysmal tachycardia. Br J Clin Pharma-col 8: 441, 1979.

    Google Scholar 

  382. G. Hartel, A. Louhija, A. Konttimen: Disopyramide in the prevention of reccurrent atrial fibrillation after electroconversion. Clin Pharmacol Ther 15: 551, 1974.

    Google Scholar 

  383. B. W. Karlson, I. Tortensson, C. Alyorn, S. O. Jansson, L. E. Peterson: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: A placebo controlled one year follow-up study. Euro Heart J 9: 284, 1988.

    Google Scholar 

  384. M. Ito, S. Onodera, J. Hashimoto, H. Noshiro, S. Shinoda, M. Nagashima, H. Suzaki: Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period. Am J Cardiol 63: 561, 1989.

    Google Scholar 

  385. P. Della-Bella, C. Tondo, G. Marenzi, C. M. Cipolla, F. Doni, S. Graji, A. Rimondini, A. Salvioni, M. D. Griazzi: Facilitating influence of disopyramide on atrial flutter termination by overdrive pacing. Am J Cardiol 61: 1046, 1988.

    Google Scholar 

  386. P. Brugada, H. J. Wellens: Effects of intravenous and oral disopyramide on paroxysmal atrioventricular nodal tachycardia. Am J Cardiol 53: 88, 1984.

    Google Scholar 

  387. S. Swiryn, R. A. Bauernfeind, C. R. Wyndham, R. C. Dhengra, I. Palileo, B. Strasberg, K. M. Rosen: Effects of oral disopyramide phosphate on induction of paroxysmal supraventricular tachycardia. Circ 64: 169, 1981.

    Google Scholar 

  388. D. H. Bennett: Disopyramide in patients with the Wolff Parkinson White syndrome and atrial fibrillation. Chest 74: 624, 1978.

    Google Scholar 

  389. R. A. Spurrell, C. W. Thorburn, J. Camm, E. Sowton, D. C. Deuchar: Effects of disopyramide in electrophysiologic properties of specialized conduction systems in man and on accessory atrioventricular pathway in Wolff Parkinson White syndrome. Br Heart J 37: 861, 1975.

    Google Scholar 

  390. P. W. Willis: The clinical scope of disopyramide seven years after introduction — an overview. Angiol 38: 165, 1987.

    Google Scholar 

  391. F. Morady, M. M. Scheinman, J. Desai: Disopyramide. Ann Inter Med 96: 337, 1982.

    Google Scholar 

  392. F. Narcarella, D. Bracchetti, M. Palmieri, I. Cantelli, P. Bertaccini, E. Ambrosioni: Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo controlled, double-blind, randomized crossover study. Am Heart J 109: 833, 1985.

    Google Scholar 

  393. C. M. Pratt, S. M. Batman, J. B. Young, M. Knoll, L. D. English: Antiarrhythmic efficacy of Ethmozine (moricizine HCI) compared with disopyramide and propranolol. Am J Cardiol 60: 52F, 1987.

    Google Scholar 

  394. J. Kjekshus, J. Bathen, O. M. Orning, L. Storstein: A double blind, crossover comparison of flecainide acitate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 53: 72B, 1984.

    Google Scholar 

  395. B. B. Lerman, H. L. Waxman, A. E. Buxton, M. E. Josephson: Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 51: 759, 1983.

    Google Scholar 

  396. L. A. Vismara, Z. Vera, R. R. Miller, D. K. Glason: Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. Am J Cardiol 39: 1028, 1977.

    Google Scholar 

  397. D. G. Bendett, E. L. Pritchett, A. G. Wallace, J. J. Gallagher: Recurrent ventricular tachycardia in man: evaluation of disopyramide therapy by intracardiac electrical stimulation. Eur J Cardiol 9: 255, 1979.

    Google Scholar 

  398. N. Riccioni, M. Castiglioni, C. Bartolonili: Disopyramide induced QT prolongation and ventricular tachyarrhythmias. Am Heart J 105: 870, 1983.

    Google Scholar 

  399. D. Tzivoni, D. Keren, S. Stern, S. Gottleib: Disopyramide induced Torsade de Pointes. Arch Inter Med 141: 946, 1981.

    Google Scholar 

  400. R. S. Meltzer, E. W. Robert, M. McMorrow, R. P. Martin: Atypical ventricular tachycardia as a manifestation of disopyramide toxicity. Am J Cardiol 42: 1049, 1978.

    Google Scholar 

  401. J. M. Desai, M. M. Scheinman, D. Hirschfeld, R. Gonzales, R. W. Peters: Cardiovascular collapse associated with disopyramide therapy. Chest 79: 545, 1981.

    Google Scholar 

  402. J. L. Bauman, J. Gallastegui, B. Strasberg, S. Swiryn, J. Hoff, W. J.Welch, R. A. Bauernfeind: Long-term therapy with disopyramide phosphate: side effects and effectiveness. Am Heart J 111: 654, 1986.

    Google Scholar 

  403. L. H. Danziger, J. R. Horn: Disopyramide induced urinary retention: Report of nine cases and review of the literature. Arch Inter Med 143: 1683, 1983.

    Google Scholar 

  404. S. L. Teichmann, J. D. Fisher, J. A. Matos, S. G. Kim: Disopyramide — pyridostigmine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 7: 108, 1985.

    Google Scholar 

  405. B. F. Hoffman: The action of quinidine and procainamide in single fiber of drug ventricle and specialized conducting system. Ann Acad Bras Clin 29: 365, 1958.

    Google Scholar 

  406. F. Morady, L. A. DiCarlo, J. M. Baerman, R. B. Krol: Rate-dependent effects of intravenous lidocaine, procainamide and amiodarone on intraventricular conduction. J Am Coll Cardiol 6: 179, 1985.

    Google Scholar 

  407. H. I. Worske, F. I. Belford, F. N. Fastier, C. M. L. Brooks: The effect of procainamide on excitability, refractoriness and conduction in the mammelian heart. J Pharmacol Exp. Ther 107: 134, 1953.

    Google Scholar 

  408. D. M. Roden, S. B. Reele, S. B. Higgins, G. R. Wilkinson, R. F. Smith, J. A. Oates, R. L. Woosley: Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetyl procainamide in human subjetcs: comparison with procainamide. Am J Cardiol 460: 463, 1980.

    Google Scholar 

  409. K. H. Dongman, B. F. Hoffman: Effects of N-acetyl procainamide on cardiac Purkinje fibers. Pharmacol 20: 150, 1978.

    Google Scholar 

  410. D. Goldberg, J. A. Reiffel, J. C. Davis, E. Gang, F. Livelli, J. T. Bigger: Electrophysiologic effects of procainamide on sinus node function in patients with and without sinus node disease. Am Heart J 103: 75, 1982.

    Google Scholar 

  411. M. Shenasa, C. J. Gilbert, D. H. Schmidt, M. Akhtar: Procainamide and retrograde atrioventricular nodal conduction in man. Circ 65: 355, 1982.

    Google Scholar 

  412. M. E. Josephson, A. R. Caracta, M. H. Riccuiti, S. H. Lau, A. N. Damato: Electrophysiologic properties of procainamide in man. Am J Cardiol 33: 596, 1974.

    Google Scholar 

  413. W. D. M. Paton, J. W. Thompson: The ganglion blocking action of procainamide. Br J Pharmacol 22: 143, 1964.

    Google Scholar 

  414. E. G. V. Giardina, R. H. Heissenbutel, J. T. Bigger: Intermittent intravenous procainamide to treat ventricular arrhythmias: Correlation of plasma concentration with effect on arrhythmia, electrocardiogram and blood pressure. Ann Intern Med 78: 183, 1973.

    Google Scholar 

  415. E. G. V. Giardina, P. E. Fenster, J. T. Bigger, M. Mayersohn, D. Perrier, F. I. Marcus: Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation. Am J Cardiol 46: 855, 1980.

    Google Scholar 

  416. C. Gaffner, G. Johnson, J. Sjogren, Pharmacokinetics of procainamide intravenously, orally as conventional and slow release tablets. Clin Pharma-col Ther 17: 414, 1975.

    Google Scholar 

  417. J. Koch Weser, S. M. Klein: Procainamide dosage schedules, plasma concentrations and clinical effects. J Am Med Assoc 215: 1454, 1971.

    Google Scholar 

  418. E. G. V. Giardina, J. Dreifuss, J. T. Bigger, J. M. Shaw, E. C. Schreiber: Metabolism of procainamide in normal and cardiac subjects. Clin Pharmacol Ther 19: 339, 1976.

    Google Scholar 

  419. R. L. Woosley, D. E. Drayer, M. M. Reidenberg, A. S. Nies, K. Carr, J. E. Oates: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298: 1157, 1978.

    Google Scholar 

  420. J. M. Strong, J. S. Dutcher, W. K. Lie, A. J. Atkinson: Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharmacokinet Biopharm 3: 223, 1975.

    Google Scholar 

  421. D. E. Drayer, D. J. Lowenthal, R. L. Woosley, A. J. Nies, A. Schwartz, M. M. Reidenberg: Cummulation of N-acetylprocainamide, an active metabolite of procainamide in patients with impaired renal function. Clin Pharmacol Ther 22: 63, 1977.

    Google Scholar 

  422. J. J. C. Lertora, D. Block, D. P. Stec: Effects of N-acetylprocainamide and procainamide on myocardial contractile force, heart rate ad blood pressure. Proc Soc Exp Biol Med 161: 332, 1979.

    Google Scholar 

  423. E. Angelakos, E. Hastings: The influence of quinidine and procainamide on myocardial contractility in vivo. Am J Cardiol 5: 791, 1960.

    Google Scholar 

  424. J. R. Burton, M. T. Matthew, P. W. Armstrong: Comparative effects of lidocaine and procainamide on acute impaired hemodynamics. Am J Med 61: 215, 1962.

    Google Scholar 

  425. R. L. McClendon, W. R. Hansen, J. M. Kinsman: Hemodynamic changes following procanamide administration. Am J Med Sci 222: 375, 1951.

    Google Scholar 

  426. P. E. Fenster, K. A. Comess, R. Marsh, C. Katzenberg, W. D. Hager: Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 106: 501, 1983.

    Google Scholar 

  427. G. Miller, J. L. Weinberg, A. Pick: The effect of procainamide in clinical ventricular fibrillation and flutter. Circ 6: 41, 1952.

    Google Scholar 

  428. S. W. Halpern, G. Ellrodt, B. H. Singh, W. J. Mandel: Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: Relation to left atrial size. Br Heart J 44: 589, 1980.

    Google Scholar 

  429. B. Olshansky, K. Okumura, P. G. Hess, R. W. Henthorn, A. L. Waldo: Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardio 11: 359, 1988.

    Google Scholar 

  430. P. Wu, P. Dines, R. Bauernfeind, R. Kehar, F. Amat-y-Leon, K. M. Rosen: Effects of procainamide on atrioventricular nodal reentrant paroxysmal tachycardia. Circ 57: 1171, 1978.

    Google Scholar 

  431. W. I. Mandel, M. M. Laks, K. Obayashi, H. Hayakawa, W. Daley: The Wolff Parkinson White Syndrome: Pharmacologic effects of procainamide. Am Heart J 90: 744, 1975.

    Google Scholar 

  432. T. D. Sellers, R. W. Campbell, T. M. Bashore, J. J. Gallagher: Effects of procainamide and quinidine sulfate in the Wolff Parkinson White syndrome. Circ 35: 15, 1977.

    Google Scholar 

  433. H. J. J. Wellens, S. Braat, P. Brugada, A. P. M. Gorgets, F. W. Bar: Use of parocainamide in patients with the Wolff Parkinson White syndrome to disclose a short refractory period of the accessory pathway. Am J Cardiol 50: 1087, 1982.

    Google Scholar 

  434. H. J. Kayden, B. B. Brodel, J. M. Skele: Procainamide: a review. Circ 15: 118, 1957.

    Google Scholar 

  435. T. J. Bigger, R. A. Heissenbuttel: The use of procainamide and lidocaine in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis 11: 515, 1969.

    Google Scholar 

  436. R. A. Winkle, A. H. Gradman, J. W. Fitzgerald, P. A. Bill: Antiarrhythmic drug effects assessed from ventricular arrhythmia reduction in the ambulatory electrocardiogram and treadmill test: comparison of propanolol, procainamide and quinidine. Am J Cardiol 42: 473, 1978.

    Google Scholar 

  437. K. Arakawa, Y. Poi, K. Hashiba, T. Mitsuoka, T. Yanaga, Y. Hata, N. Ogawa: Well controlled comparative study of the clinical efectiveness of intravenous mexiletine and procainamide in ventricular premature contractions. Am Heart J 25: 357, 1984.

    Google Scholar 

  438. C. Lidell, N. Rehnquist, A. Sjoren, R. J. Yli-Uotila, P. K. Ronnevik: Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: A multicenter study. Am Heart J 109: 970, 1985.

    Google Scholar 

  439. K. Nademanee, G. Feld, J. Hendrickson, V. Intarachot, C. Yale, M. K. Heng, B. H. Singh: Mexiletine: Double blind comparison with procainamide in PVC suppression and open label sequential comparison with amiodarone in life-threatening ventricular arrhythmias. Am Heart J 110: 923, 1985.

    Google Scholar 

  440. A. M. Greenspan, L. N. Horowitz, S. R. Spielman, M. E. Josephson: Large dose procainamide for ventricular tachyarrhythmia. Am J Caridol 46: 453, 1980.

    Google Scholar 

  441. T. R. Engel, A. del Gonzalez, S. G. Meister, W. S. Frankle: Effect of procainamide on induced ventricular tachycardia. Clin Pharmacol Ther 24: 274, 1978.

    Google Scholar 

  442. H. J. J. Willens, F. W. Bar, K. I. Lie, D. R. Duren, H. J. Dohmen: Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. Am J Cardiol 40: 579, 1977.

    Google Scholar 

  443. H. C. Waxman, A. E. Buxton, L. M. Sadowski, M. E. Josephson: The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmia predicts the response to other medications. Circ 67: 30, 1983.

    Google Scholar 

  444. D. G. Wyse, B. Mitchell, H. J. Duff: Procainamide, disopyramide and quinidine. Discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia. J Am Coll Cardiol 9: 882, 1987.

    Google Scholar 

  445. D. S. Oseran, E. S. Gang, M. E. Rosenthal, W. J. Mandel, T. Peter: Electropharmacologic testing in sustained ventricular tachycardia associated with coronary heart disease: Value of the response to intravenous procainamide in predicting the response to oral procainamide and oral quinidine treatment. Am J Cardiol 56: 883, 1985.

    Google Scholar 

  446. P. H. Lawson, H. Jick: Adverse reactions to procainamide. Br J Clin Pharmacol 4: 507, 1977.

    Google Scholar 

  447. B. Strasberg, S. Sclarovsky, A. Erdberg, C. E. Duffy, W. Lam, S. Swiryn, J. Agmon, K. M. Rosen: Procainamide induced polymorphous ventricular tachycardia. Am J Cardiol 47: 1309, 1981.

    Google Scholar 

  448. K. Rothman, E. L. Amorosi: Procainamide induced agranulocytosis and thrombocytopenia. Arch Intern Med 139: 246, 1979.

    Google Scholar 

  449. B. D. Kosowsky, J. Taylor, B. Lown, R. F. Ritchie: Long-term use of procainamide following acute myocardial infarction. Circ 42: 1204, 1973.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Section of Cardiology, Boston University School of Medicine, Boston, MA, 02118, USA

    Philip J. Podrid, Lisa Mendes, Scott L. Beau & John S. Wilson

Authors
  1. Philip J. Podrid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Mendes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott L. Beau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John S. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Basel, Schweiz

    Ernst Jucker

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Basel AG

About this chapter

Cite this chapter

Podrid, P.J., Mendes, L., Beau, S.L., Wilson, J.S. (1990). The oral antiarrhythmic drugs. In: Jucker, E. (eds) Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Progress in Drug Research, vol 35. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7133-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7133-4_6

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-7135-8

  • Online ISBN: 978-3-0348-7133-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation